NovaBridge Biosciences · NASDAQ:NBP
NovaBridge Biosciences — Technical Presentation (March 2026)
34 slides from NovaBridge Biosciences's technical presentation, Mar 9, 2026
Slide 1: VIS-101 Phase 2a Update: Clinical Results and Next Steps
VIS-101 Phase 2a Update Clinical Results and Next Steps March 9, 2026
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by NovaBridge Biosciences (the “Company”) solely for informational purposes. Certain of the information included herein was obtained from various sources, including certain third parties, and has not been independently verified by the Company. By viewin
Slide 3: Today's Agenda
NovaBridge Biosciences and Visara, the 1st Spoke VIS-101 Phase 2a Update VIS-101 KOL Perspective VIS-101 Next Steps Q&A Today’s Agenda 2
Slide 4: Today's Speakers
Today’s Speakers Emmett T. Cunningham, Jr., MD, PhD, MPH Executive Chairman, Co-Founder, Visara Vice Chairman of the Board, NovaBridge Carlos Quezada-Ruiz, MD, FASRS Chairman, Scientific Advisory Board, Visara Cadmus Rich, MD, MBA Chief Medical Officer, Visara Nikolas JS London, MD, FACS Managing Pa
Slide 5: NovaBridge Biosciences: Accelerating Access to Innovation
NovaBridge Biosciences Accelerating Access to Innovation 4
Slide 6: NovaBridge: Accelerating Access to Innovation
NovaBridge: Accelerating Access to Innovation Global biotech platform with a portfolio of first- and best-in-class programs Two lead assets with compelling clinical proof-of-concept supporting differentiated positioning VIS-101: Differentiated VEGF-A/ANG-2 bispecific with favorable safety profile an
Slide 7: Hub-and-Spoke Gateway Connecting Global Markets
Well-positioned to Deliver Innovation from Emerging Biopharma Ecosystems to Patients Globally We are a Hub-and-Spoke Gateway Connecting Global Markets Discovery Pre-clinical development Clinical PoC Late phase development Registration Commerciali- zation 5-10X value creation Acquire early-stage asse
Slide 8: Transaction Structure
Transaction Structure Visara, Inc. NovaBridge AffaMed ESOP 65% 30% 5% NovaBridge invested cash for 65% equity interest in Visara AffaMed contributed its rights and interests in VIS-101 for 30% of the equity interest in Visara The remaining 5% equity interest in Visara reserved for an ESOP VIS-101-re
Slide 9: Visara, Inc. NovaBridge's 1st Spoke
Visara, Inc. NovaBridge’s 1st Spoke 8
Slide 10: VIS-101 – Purpose-Designed to be Best-in-Class for Retinal Vascular Diseases
VIS-101 – Purpose-Designed to be Best-in-Class for Retinal Vascular Diseases Anti-Ang-2 Anti-VEGF-A Modified Fc Phase 2a wet AMD Update Safe and well-tolerated Rapid, robust, and durable treatment responses Mean BCVA >10 ETDRS letters Median CST 100-150 µm Potentially best in class durability: ~Two-
Slide 11: Today's Speakers
A leading vitreoretinal surgeon and clinical scientist who directs a prominent, nationally recognized retinal practice and has served as the Principal Investigator for dozens of clinical trials evaluating the next generation of surgical and medical therapies An internationally recognized retina spec
Slide 12: VIS-101 Overview
VIS-101 Overview Visara
Slide 13: $15B Total Branded Anti-VEGF-A Market
$15B Total Branded Anti-VEGF-A Market1 DME Wet AMD RVO 20M+ 21M+ 16M+ More than 57M people affected globally2 Data source: 1. Ophthalmic Anti-VEGF Therapeutics Market Size & Share 2025 – 2034, published December 2025, 2. Invest Ophthalmol Vis Sci. 2021 Nov 24; 62 (14): 26. doi: 10.1167/iovs.62.14.26
Slide 14: Anti-VEGF Ophthalmology Market Growth Driven by Efficacy and Durability
Global revenue projected to grow to >$20B by 2030 Increased revenue correlates with improved durability Lucentis® Q4W Eylea® Q8W Revenue 2y from Launch $1.8B $2.8B Vabysmo® Q8-16W Eylea HD® Q8-16W $4.4B $1.5B VIS-101 $1B+* Early Data Support VIS-101’s Potential for Best-in-Class Durability Q8-24W+ A
Slide 15: VIS-101: Purpose-Designed Dual VEGF-A x ANG-2 Inhibitor
Bispecific, Tetravalent design: increased binding sites and increased VEGF-A and ANG-2 affinity Optimized Fc region for shortened plasma half-life Humanized anti-VEGF-A mAb ~2X inhibitory activity Anti-Ang-2 inhibitory peptides (18mers) ~17X inhibitory activity, for class leading durability ~Half of
Slide 16: VIS-101: Best-in-Class Intravitreal Half-Life and Dual Target Inhibition
Anti-VEGF-A Anti-Ang-2 Modified Fc 4 doses Up to 16 weeks Purpose-Bioengineered for Rapid, Robust, Durable Response Name/Company: Status Vabysmo®/Faricimab Roche: Approved VIS-101 Visara: Phase 2 Structure Antibody format Molecular Weight Dose (mg/nM) IC50: VEGF/ANG-21 Bispecific ~150 kDa 6 mg 292 p
Slide 17: Predictive Modeling Suggests Best-in-Class Potential for VIS-101
Predicted dynamics of intraocular VEGF-A and ANG-2 suppression through week 32 post dose1,2 Longer VEGF-A and ANG-2 inhibition may predict increased VIS-101 durability Predictive Modeling Suggests Best-in-Class Potential for VIS-101 1. Diack et al,2024, TVST: https://doi.org/10.1167/tvst.13.11.14, h
Slide 18: VIS-101 Phase 2a Update
VIS-101 Phase 2a Update Dr. Carlos Quezada-Ruiz 17
Slide 19: VIS-101: Phase 2a Study Overview
4 doses Up to 16 weeks Study Assessed Safety and Tolerability of VIS-101, Time to Retreatment After Loading Doses 6 mg (n=25) 3 mg (n=13) Monthly follow-up to Week 36 or retreatment Patient criteria: Aged 50-80 years with wet AMD (both treatment naïve and pre-treated) BCVA ETDRS letter score 78-19 C
Slide 20: Phase 2a Study Demographics Represent Wet AMD Patients
Baseline characteristics were similar between the 6mg and 3mg cohorts Patient Characteristics 6mg (N=25) 3mg (N=13) Total (N=38) Age (average), years 69.5 71.5 Sex, (n, %) Male 17 (68.0) 8 (61.5) 25 (65.8) Female 8 (32.0) 5 (38.5) 13 (34.2) Baseline BCVA (Letters) 54.7 52.3 53.9 Baseline CST (μm) 41
Slide 21: Rapid, Robust and Sustained Vision Improvement After Three Loading Doses
VIS-101 (3 loading doses) Source: nAMD China Phase 2a final raw dataset (tab BCVA001_1) – not final analysis Notes: *One patient in the 6mg naïve patient cohort dropped out after week 8 follow-up. **One patient in the 6mg pre-treated cohort dropped out after week 4 visit for reasons unrelated to stu
Slide 22: VIS-101 – Robust Efficacy, Best-in-Class Potential
Q12W VIS-101 (3 intravitreal injections) Treatment Interval: 12-16 weeks Treatment Free: up to 28 weeks VIS-101 6mg – Retreatment free Patients Faricimab 6mg (All Treatment Naïve) Treatment free Less loading doses Faricimab (4 intravitreal injections) Faricimab, Q16W (n=31) Ranibizumab, 0.5mg, Q4W (
Slide 23: VIS-101 – Robust Durability, Best-in-Class Potential
% Participants Remaining Treatment Free (16 vs. 24 weeks post loading doses) VIS-101 (3 loading doses) Treatment-Naïve - Retreatment free Patients (7/9) (7/11) (3/9) (5/11) * # * 3mg (n=9 randomized) 6mg (n=12* randomized) Source: nAMD China Phase 2a final raw dataset (tab BCVA001_1) – not final ana
Slide 24: VIS-101 – Rapid and Robust CST Improvement
3mg – Retreatment free Patients 6mg – Retreatment free Patients * ** VIS-101 (3 loading doses) VIS-101 (3 loading doses) Treatment Naïve Pre-Treated Source: nAMD China Phase 2a final raw dataset (tab BCVA001_1) – not final analysis Notes: *One patient in the 6mg naïve patient cohort dropped out afte
Slide 25: VIS-101 - Sustained CST Improvement
Mean CST Changes (Treatment-Naïve) (7/9) (7/11) (3/9) (5/11) * * 3mg (n=9 randomized) 6mg (n=12* randomized) VIS-101 (3 loading doses) % Participants Remaining Treatment Free (16 vs. 24 weeks post loading doses) (7/9) (7/11) (3/9) (5/11) * Source: nAMD China Phase 2a final raw dataset (tab BCVA001_1
Slide 26: VIS-101 - Best-in-Class Durability Potential
Source: nAMD China Phase 2a final raw dataset (tab TREAT001_1) Faricimab Phase 3 data; 16 weeks after loading. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3
Slide 27: VIS-101 - Favorable Safety Profile with No Dose-Limiting Toxicity
Source: ASKG712-CT-I-1_Phase 1/2a Top Line Table 14.3.2.5, *2 events one with a grade change, System Organ Class/Preferred Term (SOC/PT) SOC/PT 3mg (N=13) n(%) E 6mg (N=25) n(%) E Total Treatment Related TEAE 0 2 ( 8 ) 4 Eye Disorder 0 2 ( 8 ) 4 Uveitis 0 1 ( 4 ) 3* Vitreous opacities 0 1 ( 4 ) 1 *U
Slide 28: KOL Perspective: Dr. Nikolas London
KOL Perspective: Dr. Nikolas London 27
Slide 29: VIS-101: Best-in-Class Intravitreal Half-Life and Dual Target Inhibition
Anti-VEGF-A Anti-Ang-2 Modified Fc 4 doses Up to 16 weeks Purpose-Bioengineered for Rapid, Robust, Durable Response Name/Company: Status Vabysmo®/Faricimab Roche: Approved VIS-101 Visara: Phase 2 Structure Antibody format Molecular Weight Dose (mg/nM) IC50: VEGF/ANG-21 Bispecific ~150 kDa 6 mg 292 p
Slide 30: VIS-101: Next Steps
VIS-101: Next Steps Visara
Slide 31: VIS-101 – Purpose-Designed to be Best-in-Class; Next Steps
VIS-101 – Purpose-Designed to be Best-in-Class for Retinal Vascular Diseases Anti-Ang-2 Anti-VEGF-A Modified Fc Phase 2a wet AMD Update Safe and well-tolerated Rapid, robust, and durable treatment responses Potentially best in class durability Next Steps: Phase 2b study expected to be initiated H2 2
Slide 32: VIS-101: Q&A
VIS-101: Q&A Visara
Slide 33: Thank you
Thank you www.novabridge.com IR@novabridge.com
Slide 34: Summary of Disclosures
33 Affamed, Principal Investigator Allergan/Abbvie, Consultant Amgen, Principal Investigator Apellis Pharmaceuticals Inc, Consultant, Speaker Astellas Pharmaceuticals, Speaker Eyepoint, Consultant and Principal Investigator Boehringer Ingelheim, Principal Investigator Genentech/Roche, Consultant and
NovaBridge Biosciences — Technical Presentation (March 2026) on 6ix